Cline Darren S 4

What Happened

• Darren S. Cline, a director of Pyxis Oncology, was granted a derivative award covering 45,867 shares on 2026-03-24. The reported acquisition price is $0.00 (no cash paid at grant), and the award is recorded as a derivative security (Form 4 code A — grant/award).
• This is a compensation grant rather than an open-market purchase or sale; such awards are commonly part of director compensation and do not by themselves indicate a buy/sell signal.

Key Details

• Transaction date: 2026-03-24; Filing date (Form 4): 2026-03-25 (filed promptly).
• Price reported: $0.00 per share; reported amount: 45,867 shares; total reported cash value: $0.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The shares subject to this option/award will vest 100% on the first anniversary of the grant date, contingent on the reporting person's continued service through the vesting date (Footnote F1).
• Transaction type: Derivative grant (code A). No 10b5-1 plan, tax withholding, or sale-related codes noted.

Context

• Because this is a grant (derivative award) with future vesting, the shares are not immediately tradable; they convert to vested shares only if vesting conditions are met. Compensation grants are routine for executives and directors and should be viewed as part of pay, not an immediate market-based endorsement.